Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 18, Issue 6, Pages (September 2015)

Published byPatience Ferguson Modified over 6 years ago

Similar presentations

Presentation on theme: "Volume 18, Issue 6, Pages (September 2015)"— Presentation transcript:

1 Volume 18, Issue 6, Pages 774-782 (September 2015)
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin- Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small- Cell Lung Cancer in the United States  Jie Ting, PhD, MSPH, Tien Ho PharmD , Pin Xiang, PharmD, Amanda Sugay, PharmD, Maher Abdel-Sattar, PharmD, Leslie Wilson, PhD  Value in Health  Volume 18, Issue 6, Pages (September 2015) DOI: /j.jval Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2 Fig. 1 Progression-free survival (PFS) curves for erlotinib (EURTAC [15]), afatinib (LUX-Lung 3 [16]), and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive NSCLC. The declining exponential approximation for calculating life expectancy method was used to extrapolate the PFS from 32 to 36 months in EURTAC [15] and from 24 to 36 months in LUX-Lung 3 [16]. EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer. (Color version of figure is available online.) Value in Health  , DOI: ( /j.jval ) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3 Fig. 2 Acceptability curve for erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive NSCLC. (A) Base-case analysis. Monthly survival estimates in EURTAC (erlotinib trial) [15] were corrected for participants with poorer ECOG performance status compared with those in LUX-Lung 3 (afatanib trial) [16]. (B) Without correction of the monthly survival estimates in EURTAC. ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer; QALY, quality-adjusted life-year. (Color version of figure is available online.) Value in Health  , DOI: ( /j.jval ) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4 Fig. 3 The expected value for further information for US patient population aged 60 years or older undergoing first-line treatment for advanced EGFR mutation-positive NSCLC. EGFR, epidermal growth factor receptor; EVPI, expected value of perfect information; NSCLC, non–small cell lung; QALY, quality-adjusted life-year. (Color version of figure is available online.) Value in Health  , DOI: ( /j.jval ) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Download ppt "Volume 18, Issue 6, Pages (September 2015)"

Similar presentations

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.

Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.
Volume 14, Issue 8, Pages (December 2011)

Volume 14, Issue 8, Pages (December 2011)
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Volume 15, Issue 2, Pages (March 2012)

Volume 15, Issue 2, Pages (March 2012)
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.
Volume 15, Issue 2, Pages (March 2012)

Volume 15, Issue 2, Pages (March 2012)
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Examining the Value of Menopausal Symptom Relief Among US Women

Examining the Value of Menopausal Symptom Relief Among US Women
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies  A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold 

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies  A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold 
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers  Christos.

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non–Small Cell Lung Cancers  Christos.
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Similar presentations

Ads by Google